TSUMURA & CO.
Stock Code:
4540
Market:
TSE Prime
Sector:
Pharmaceutical
Print

Stock Price Index
2026/10/07 15:30
  • Close Price 3,749.0
  • Change +24.0
    +0.64 %
  • Volume 324,700
Price/Book 0.75
Forward P/E 10.98
Forward Div Yield 4.21%
Market Cap 287.7B
Company Profile

Beginning with its founding in 1893, the Tsumura Group core business has been the manufacture and sales of pharmaceuticals made from crude drugs derived from plants and other natural products, and our share of the domestic prescription Kampo formulation market exceeds 80%.
In addition to steady growth in our domestic business, we have begun full-scale business in China since 2017 and have been building a business foundation to become a medium- to long-term growth driver. Through our business in China, we aim to contribute to develop the Chinese traditional medicine industry.
In our long-term management vision for 2031, “TSUMURA VISION “Cho-WA” 2031”, we aim to contribute to well-being through evidence-based provision of Kampo and traditional Chinese treatments and other products and services tailored to the individual’s life stage, symptoms, genetic makeup and living environment.

Major Shareholders
As of March 31,2026
Principal Shareholders Share held Percentage of Shareholding(%)
1 The Master Trust Bank of Japan, Ltd. (Trust Account) 11,780 15.65
2 BOCHK FOR PING AN LIFE INSURANCE COMPANY OF CHINA LTD 7,675 10.20
3 STATE STREET BANK AND TRUST COMPANY 505001 4,605 6.12
4 Custody Bank of Japan, Ltd. (Trust Account) 4,109 5.46
5 BRIGHT RIDE LIMITED 1,692 2.25
6 Employees’ Stockholding 1,511 2.01
7 MUFG Bank, Ltd. 1,348 1.79
8 BNYM AS AGT/CLTS 10 PERCENT 1,315 1.75
9 THE NOMURA TRUST AND BANKING CO., LTD. (Trust Account) 1,277 1.70
10 JP MORGAN CHASE BANK 385781 983 1.31
*Note:The percentage of equity is calculated deducting 1,468,539 treasury shares.
The above treasury shares do not include 238,075 treasury shares held as trust assets of the officer remuneration BIP trust and 506,292 treasury shares held as trust assets of the share allocation ESOP trust.
Current Share Status
比率(Ratio)
Japanese financial institutions 29.90%
Japanese securities firms 2.13%
Japanese corporations 4.26%
Overseas institutions 44.24%
Japanese individuals and others 19.47%
Perfomance and Financial Summary
Profitability & Solvency Index
ROE
DOE
Dividend
From Apr.to Sept.
From Oct. to Mar.
Ratio to total sales
■ Domestic business:Prescription Kampo Products 79.9%
■ Domestic business:OTC Kampo etc. 3.2%
■ Domestic business:Other 0.6%
■ China business 16.3%
Consolidated operating results
[M.JPY]
2023年度(FY2023) 2024年度(FY2024) 2025年度(FY2025)
Net sales 150,845 181,093 192,615
Domestic business 132,099 160,459 161,172
China business 18,745 20,633 31,442
Operating profit 20,017 40,125 35,219
Domestic business 20,531 40,136 35,024
China business -514 -10 195
Ordinary profit 23,493 42,446 40,036
Profit attributable to owners of parent 16,707 32,428 28,117
Profit per share 219.8 427.2 376.3
Consolidated financial condition
[M.JPY]
2023年度(FY2023) 2024年度(FY2024) 2025年度(FY2025)
Total assets 428,254 464,380 592,766
Net assets 295,364 330,110 371,603
Investments 21,908 31,077 37,489
Depreciation 10,235 10,620 12,291
Personnel expenses 19,503 22,056
R&D expenses 8,288 8,355 8,484
Advertising expenses 936 847
Basic earnings per share 3,566.54 3,968.05 4,315.88
Cash Flows
[M.JPY]
2023年度(FY2023) 2024年度(FY2024) 2025年度(FY2025)
Cash flows from operating activities 5,608 33,823 24,718
Cash flows from investing activities -19,351 -24,974 -50,309
Cash flows from financing activities -4,417 -19,871 32,603
※The Company has applied the Accounting Standard for Revenue Recognition from the beginning of the FY2021.
*Investments: investments in property, plant and equipment and software.